[Pubmed] Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidan
Posté : 12 nov. 2024 12:00
Pract Neurol. 2024 Nov 11:pn-2024-004228. doi: 10.1136/pn-2024-004228. Online ahead of print.
ABSTRACT
The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) in 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service for relapsing-remitting MS, early primary progressive MS and active secondary progressive MS. This updated guidance provides a consensus-based approach to using DMTs. We provide recommendations for eligibility, starting, monitoring, switching and stopping of DMTs; pregnancy; equitable access to DMT; autologous haemopoietic stem-cell transplantation; and use of generics. We highlight best practice where it exists and discuss future priorities.
PMID:39532459 | DOI:10.1136/pn-2024-004228
Source: https://pubmed.ncbi.nlm.nih.gov/3953245 ... t9+e462414